Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Bioluminescent Assay Enables Easy Measurement of Glucose Uptake

Part # PS281

Abstract

Michael P. Valley, Natasha Karassina, and Jolanta Vidugiriene
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711
Abstract # 2107

Glucose uptake is an important pharmacological target. Cancer cells support their high rates of proliferation by overexpressing glucose transporters to increase their rates of glucose uptake. In contrast, the decreased rates of glucose uptake in diabetic fat and muscle cells can lead to hyperglycemia and its inherent deleterious biological effects. Hence, effectors of glucose uptake would be useful for both anticancer therapies and diabetes management.
The standard method for measuring glucose uptake has long been the addition of a radioactive glucose analog (2-deoxyglucose) and measurement of the accumulation of the stable and impermeable phosphorylated derivative, 2-deoxyglucose-6-phosphate (2DG6P). In the interest of transitioning to a safer, non-radioactive assay, we have developed a simple bioluminescent glucose uptake assay that measures the production of NADPH through the oxidation of 2DG6P by glucose-6-phosphate dehydrogenase (G6PDH). This assay is both rapid and convenient and exhibits a larger signal window than comparable fluorescent or colorimetric approaches.

Printed in USA.